Lung imaging is furthermore a challenge in MRI because of the predominance of air within the lungs and associated susceptibility issues as well as low signal to noise of the inflated lung parenchyma. Cardiac and respiratory triggered or breath hold sequences allow diagnostic imaging, however a comparable image quality with computed tomography is still difficult to achieve.
Assumptions for lung MRI:
The current trends in MRI are the use of new imaging technologies and increasingly powerful magnetic fields. Among these technologies are parallel imaging techniques as well as ventilation agents like hyperpolarized helium for the use as an inert inhalational contrast agent to study lung ventilation properties. With hyperpolarized gases clear images of the lungs can be obtained without using a large magnetic field (see also back projection imaging). Single shot sequences (e.g. TSE or Half Fourier Acquisition Single Shot Turbo Spin Echo HASTE) used in lung MR imaging benefits from parallel imaging techniques due to reduced relaxation time effects during the echo train and therefore reduced image blurring as well as reduced motion artifacts.
In the future, more effective contrast agents may provide an alternative solution to the need for high field MRI. Dynamic contrast enhanced MRI perfusion has demonstrated a potential in the diagnosis of pulmonary embolism or to characterize lung cancer and mediastinal tumors. 3D contrast enhanced magnetic resonance angiography of the thoracic vessel.

See also the related poll result: 'MRI will have replaced 50% of x-ray exams by'

MS-325 is the formerly code name of gadofosveset trisodium (new trade name Vasovist). MS-325 belongs to a new class of blood pool agents for magnetic resonance angiography (MRA) to diagnose vascular disease. Gadofosveset trisodium has ten times the signal-enhancing power of existing contrast agents as well as prolonged retention in the blood. This enables the rapid acquisition of high resolution MRA's using standard MRI machines.
Gadofosveset trisodium, which is gadolinium-based, stays in the blood stream as a result of transient binding to albumin. Albumin binding offers an additional benefit beyond localization in the blood pool. The contrast agent begins to spin much more slowly, at the rate albumin spins, causing a relaxivity gain that produces a substantially brighter signal than would be possible with freely circulating gadolinium. MS-325 is an intravascular contrast agent intended for use in MRI as an aid in diagnosing aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease (PVD) or abdominal aortic aneurysm (AAA).
Currently clinical trials completed for peripheral vascular disease and coronary artery disease. Additional trials are also being conducted to evaluate MS-325 as an aid in diagnosing breast cancer and suggested that it might be feasible to combine the use of MS-325, injected during peak stress, with delayed high-resolution imaging to identify myocardial perfusion defects.
Vasovist (MS-325) would compete with the contrast agents Ferumoxytol (Code 7228) from AMAG Pharmaceuticals, Inc. and NC100150 Injection from Nycomed Amersham, but their further development is uncertain.
Partners in development: EPIX Pharmaceuticals, Inc., Mallinckrodt Inc., and Bayer Schering Pharma AG. Bayer Schering Pharma has the worldwide marketing rights for the product.
Formerly known under the Mallinckrodt trademark name, AngioMARK®.

See also Classifications, Characteristics, etc.

The activation of the brain is mirrored in the local changes in metabolism and hemodynamics (brit. haemodynamics). By using heavily T2 weighted scans activated brain areas show an increase in signal intensity as oxyhaemoglobin (brit. oxyhaemoglobin) is diamagnetic and deoxyhemoglobin (brit. deoxyhaemoglobin) is paramagnetic. Oxygen mapping will benefit from high field strength.

See also Blood Oxygenation Level Dependent Contrast, Haemoglobin, Perfusion Imaging, Diamagnetism, Paramagnetism.

Short name: P792, generic name: Gadomeritol, preliminary trade name: Vistarem™, central moiety: Gd
A macromolecular Gd-DOTA derivate under development as a MRI blood pool agent with rapid clearance. Phase II of the clinical trials on P792 (Guerbet SA) will make it possible to validate the performance of this agent in the fields of angiography, myocardial perfusion and tumor characterization.

(PRESTO) PRESTO is a 3 dimensional ultrafast gradient echo sequence that combines the whole brain coverage with T2* weighted imaging. PRESTO is useful for BOLD and perfusion imaging studies. In combination with parallel imaging techniques, PRESTO provides higher temporal resolution and more coverage compared to traditional multi slice imaging. In addition, the sensitivity to susceptibility artifacts and flow phenomena is reduced, compared with EPI techniques, enabling MRI scans throughout the brain including the skull base.

See also T2 Star.